ArticleThe Journal of allergy and clinical immunology2017
Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity.
Abstract readLetter
In one paragraph
Article in The Journal of allergy and clinical immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Safety, pharmacokinetics, and pharmacodynamics of sofnobrutinib, a novel non-covalent BTK inhibitor, in healthy subjects: First-in-human phase I study.Clinical and translational science · 2024Trial
- A phase II study of Bruton's tyrosine kinase inhibition for the prevention of anaphylaxis.The Journal of clinical investigation · 2023Trial
- Trial
- Fenebrutinib in HNature medicine · 2021Trial
- Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial.Clinical and translational science · 2021Trial
- Emerging Therapies for Anaphylaxis.Immunology and allergy clinics of North America · 2026Review
- Advances in the Management of Mediator-Related Symptoms in Non-Advanced Systemic Mastocytosis.ImmunoTargets and therapy · 2026Review
- Current and future landscape of Bruton tyrosine kinase inhibitors in allergy.The Journal of allergy and clinical immunology · 2025Review
- Targeting Bruton's tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments.Advances in rheumatology (London, England) · 2024Review
- Bruton's tyrosine kinase inhibition for the treatment of allergic disorders.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2024Review
- Mast Cell-Targeting Therapies in Mast Cell Activation Syndromes.Current allergy and asthma reports · 2024Review
- Article
- Jak out of the box: Targeting Bruton's tyrosine kinase, sialic acid-binding immunoglobulin-like lectin-8, and Janus kinase 1 in food allergy.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2023Review
- Research Advances in Mast Cell Biology and Their Translation Into Novel Therapies for Anaphylaxis.The journal of allergy and clinical immunology. In practice · 2023Review
- Bruton's tyrosine kinase inhibition for the prevention of anaphylaxis: an open-label, phase 2 trial.Research square · 2023Article
- Drug delivery targets and strategies to address mast cell diseases.Expert opinion on drug delivery · 2023Review
- Review
- Bruton's tyrosine kinase inhibition-An emerging therapeutic strategy in immune-mediated dermatological conditions.Allergy · 2022Review
- Bruton's Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives.Journal of clinical medicine · 2022Review
- Novel Bruton's Tyrosine Kinase inhibitor remibrutinib: Drug-drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling.Clinical and translational science · 2022Article
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Jennifer A ReganDivision of Allergy-Immunology and Robert H. Lurie Comprehensive Cancer Center, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill.
Yun CaoDivision of Allergy-Immunology and Robert H. Lurie Comprehensive Cancer Center, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill.
Melanie C DispenzaDivision of Allergy-Immunology and Robert H. Lurie Comprehensive Cancer Center, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill.
Shuo MaDivision of Hematology-Oncology and Robert H. Lurie Comprehensive Cancer Center, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill.
Leo I GordonDivision of Hematology-Oncology and Robert H. Lurie Comprehensive Cancer Center, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill.
Adam M PetrichDivision of Hematology-Oncology and Robert H. Lurie Comprehensive Cancer Center, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill.
Bruce S BochnerDivision of Allergy-Immunology and Robert H. Lurie Comprehensive Cancer Center, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill. Electronic address: bruce.bochner@northwestern.edu.
Funding
Northwestern University Clinical and Translational Science Institute (NUCATS)UL1TR001422 · NCATS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI D'AQUILA, RICHARD · 2015 to 2023
$56.8MTreating lung inflammation by targeting SiglecsP01HL107151 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI SCHNAAR, RONALD L · 2011 to 2017
$15.4MNorthwestern University Allergy Immunology Research Program (NUAIR)T32AI083216 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Stephanie Caroline Eisenbarth, ADAM WILLIAMS · 2010 to 2026
$4.1MTargeting Siglec-8/Siglec-F Reduce Allergic Responses In Vitro and In VivoR01AI072265 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BOCHNER, BRUCE S · 2007 to 2017
$3.9MTargeting Siglec-8/-F to treat eosinophil and mast cell related disordersR56AI072265 · NIAID · JOHNS HOPKINS UNIVERSITY · PI BOCHNER, BRUCE S · 2012 to 2012
$405kNHLBI NIH HHS P01 HL107151NIAID NIH HHS R01 AI072265NIAID NIH HHS R56 AI072265NIAID NIH HHS T32 AI083216
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdenineAgammaglobulinaemia Tyrosine KinaseAgedAllergensAnti-Allergic AgentsBasophilsHumansLymphoproliferative DisordersMaleMiddle AgedPiperidinesProtein Kinase InhibitorsPyrazolesPyrimidinesSkin TestsAdenineAgammaglobulinaemia Tyrosine KinaseAllergensAnti-Allergic AgentsibrutinibPiperidinesProtein Kinase InhibitorsPyrazolesPyrimidines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.